JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB252360

Human PD-1 ELISA Kit

Be the first to review this product! Submit a review

|

(10 Publications)

Human PD-1 ELISA Kit is a single-wash 90-min Simplestep used to quantify Human PD-1 with a sensitivity of 9.6 pg/ml. The assay uses a simple mix-wash-read protocol with just one incubation and one wash step.

- Colorimetric Sandwich ELISA - 450 nm readout : works on any standard plate reader
- Design your own immunoassay: we also offer the conjugation-ready antibody pair
- Cited in over 5 citations

View Alternative Names

CD279, PD1, PDCD1, Programmed cell death protein 1, Protein PD-1, hPD-1

6 Images
ELISA - Human PD-1 ELISA Kit (AB252360)
  • ELISA

Supplier Data

ELISA - Human PD-1 ELISA Kit (AB252360)
Sandwich ELISA - Human PD-1 ELISA Kit (AB252360)
  • sELISA

Unknown

Sandwich ELISA - Human PD-1 ELISA Kit (AB252360)

Example of human PD-1 standard curve in 1X Cell Extraction Buffer PTR.

The PD-1 standard curve was prepared as described in Section 10. Raw data values are shown in the table. Background-subtracted data values (mean +/- SD) are graphed.

Sandwich ELISA - Human PD-1 ELISA Kit (AB252360)
  • sELISA

Unknown

Sandwich ELISA - Human PD-1 ELISA Kit (AB252360)

Serum from ten individual healthy human female donors was measured in duplicate.

Interpolated dilution factor corrected values are plotted (mean +/- SD, n=2). The mean PD-1 concentration was determined to be 86.56 pg/mL with a range of 47.82 – 210.99 pg/mL.

Sandwich ELISA - Human PD-1 ELISA Kit (AB252360)
  • sELISA

Unknown

Sandwich ELISA - Human PD-1 ELISA Kit (AB252360)

Interpolated concentrations of native PD-1 in human serum, plasma samples.

The concentrations of PD-1 were measured in duplicates, interpolated from the PD-1 standard curves and corrected for sample dilution. Undiluted samples are as follows : serum neat, plasma (citrate) neat, plasma (EDTA) neat, plasma (heparin) neat. The interpolated dilution factor corrected values are plotted (mean +/- SD, n=2). The mean PD-1 concentration was determined to be 119.1 pg/mL in serum, 88.1 pg/mL in plasma (citrate) and 85.9 pg/mL in plasma (EDTA), and 92.8 pg/mL in plasma (heparin).

Sandwich ELISA - Human PD-1 ELISA Kit (AB252360)
  • sELISA

Unknown

Sandwich ELISA - Human PD-1 ELISA Kit (AB252360)

Interpolated concentrations of native PD-1 in human Molt-4 cell extract based on a 1000 ug/mL extract load and Thymus tissue extract samples based on a 500 μg/mL extract load.

The concentrations of PD-1 were measured in duplicate and interpolated from the PD-1 standard curve and corrected for sample dilution. The interpolated dilution factor corrected values are plotted (mean +/- SD, n=2). The mean PD-1 concentration was determined to be 636.9 pg/mL in Molt-4 cell extract and 566.5 pg/mL in Thymus tissue extract.

Sandwich ELISA - Human PD-1 ELISA Kit (AB252360)
  • sELISA

Unknown

Sandwich ELISA - Human PD-1 ELISA Kit (AB252360)

Example of human PD-1 standard curve in Sample Diluent NS.

The PD-1 standard curve was prepared as described in Section 10. Raw data values are shown in the table. Background-subtracted data values (mean +/- SD) are graphed.

Key facts

Detection method

Colorimetric

Sample types

Tissue Extracts, Cell culture media, Heparin Plasma, Citrate plasma, Cell culture supernatant, Serum, EDTA Plasma, Cell Extract

Reacts with

Human

Assay type

Sandwich

Results type

Quantitative

Sensitivity

= 9.6 pg/mL

Range

25 - 1600 pg/mL

Assay time

1h 30m

Assay Platform

Pre-coated microplate (12 x 8 well strips)

style
left-column

Complementary Products

Assay Kits

AB277712

Human PD-L1 ELISA Kit [28-8]

Recombinant|SimpleStep

ELISA - Human PD-L1 ELISA Kit [28-8] (AB277712)

  • 0
  • 0
Assay Kits

AB231928

Human PD-L2 ELISA Kit

Recombinant|SimpleStep

Sandwich ELISA - Human PD-L2 ELISA Kit (AB231928)

  • 0
  • 0
Assay Kits

AB264616

Human CTLA-4 ELISA Kit

Recombinant|SimpleStep

Sandwich ELISA - Human CTLA-4 ELISA Kit (AB264616)

  • 0
  • 0
Primary Antibodies

AB52587

Anti-PD1 antibody [NAT105]

BOND RX™ Validated|Recombinant

Immunohistochemistry (Frozen sections) - Anti-PD1 antibody [NAT105] (AB52587)

  • 5
  • 9
style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "sELISA": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }
style
left-column

Product details

Human PD-1 ELISA Kit ab252360 is a rapid single-wash 90-min Sandwich ELISA to measure Human PD-1 in cell culture media, cell culture supernatant, citrate plasma, EDTA plasma, heparin plasma, serum, tissue extracts. This SimpleStep sensitivity is 9.6 pg/mL.

How the assay works

Human PD-1 SimpleStep ELISA®employs capture antibodies conjugated to an affinity tag that is recognized by the monoclonal antibody used to coat our SimpleStep ELISA® plates. This approach to sandwich ELISA allows the formation of the antibody-analyte sandwich complex in a single step, significantly reducing assay time. See the SimpleStep ELISA® protocol summary in the image section for further details.

Assay Specificity

Our SimpleStep ELISA® kits use recombinant monoclonal antibodies rigorously validated to ensure the highest level of consistency and reproducibility, improved sensitivity and specificity and ease of scalability and security of supply.
Please refer to our protocol booklet for more details.

Human PD-1 ELISA Kit ab252360 protocol summary

1. Mix: add samples/standards to the wells together with the capture and detector antibody cocktail. Incubate 1 hr at room temperature
2. Wash
3. Add TMB development solution - incubate for 10 min
4. Add Stop solution
5. Read the results on a plate reader at 450 nm

Design your own immunoassay

We offer the antibody pair used in this kit in a BSA and Azide-free format, ready for conjugation:

- Anti-PD1 antibody [EPR22234-42] - BSA and Azide free (Capture) ab259656
- Anti-PD1 antibody [EPR22234-127] - BSA and Azide free (Detector) ab259656

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

style
left-column

Precision

[ { "reproducibilityType": "Inter", "sample": "Serum", "replicates": 3, "mean": null, "standardDeviation": null, "coefficientOfVariability": "9.6" }, { "reproducibilityType": "Intra", "sample": "Serum", "replicates": 8, "mean": null, "standardDeviation": null, "coefficientOfVariability": "2.4" } ]
style
left-column

Recovery

[ { "sample": "Serum", "range": "90 - 96 %", "average": "= 93" }, { "sample": "EDTA Plasma", "range": "93 - 97 %", "average": "= 95" }, { "sample": "Cell culture media", "range": "93 - 97 %", "average": "= 95" }, { "sample": "Tissue Extracts", "range": "101 - 104 %", "average": "= 102" }, { "sample": "Heparin Plasma", "range": "90 - 94 %", "average": "= 92" }, { "sample": "Citrate plasma", "range": "93 - 96 %", "average": "= 94" }, { "sample": "Cell Lysate", "range": "95 - 100 %", "average": "= 98" } ]
style
left-column

What's included?

{ "values": { "1x96Tests": { "sellingSize": "1 x 96 Tests", "publicAssetCode":"ab252360-1x96Tests", "assetComponentDetails": [ { "size":"1 x 12 mL", "name":"Stop Solution", "number":"AB252360-CMP07", "productcode":"" }, { "size":"1 x 6 mL", "name":"Antibody Diluent CPI2", "number":"AB252360-CMP13", "productcode":"" }, { "size":"1 x 20 mL", "name":"10X Wash Buffer PT (ab206977)", "number":"AB252360-CMP12", "productcode":"" }, { "size":"1 x 50 mL", "name":"Sample Diluent NS (ab193972)", "number":"AB252360-CMP05", "productcode":"" }, { "size":"1 x 600 µL", "name":"10X Human PD-1 Capture Antibody", "number":"AB252360-CMP02", "productcode":"" }, { "size":"2 x 1 Vial", "name":"Human PD-1 Lyophilized Recombinant Protein", "number":"AB252360-CMP04", "productcode":"" }, { "size":"1 x 10 mL", "name":"5X Cell Extraction Buffer PTR (ab193970)", "number":"AB252360-CMP10", "productcode":"" }, { "size":"1 x 600 µL", "name":"10X Human PD-1 Detector Antibody", "number":"AB252360-CMP03", "productcode":"" }, { "size":"1 x 1 Unit", "name":"SimpleStep Pre-Coated 96-Well Microplate (ab206978)", "number":"AB252360-CMP06", "productcode":"" }, { "size":"1 x 12 mL", "name":"TMB Development Solution", "number":"AB252360-CMP08", "productcode":"" }, { "size":"1 x 1 Unit", "name":"Plate Seals", "number":"AB252360-CMP11", "productcode":"" }, { "size":"1 x 1 mL", "name":"50X Cell Extraction Enhancer Solution (ab193971)", "number":"AB252360-CMP09", "productcode":"" } ] } } }
style
left-column

Properties and storage information

Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
+4°C
Storage information
+4°C
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

PD1 also known as Programmed Cell Death Protein 1 or PDCD1 is a transmembrane protein that plays a critical role in regulating immune responses. It has a mass of approximately 55 kDa. PD1 is expressed on the surface of T cells B cells and some myeloid cells. PD1’s expression increases upon activation of these immune cells assisting in maintaining peripheral tolerance. Researchers often use PD1 mouse models and chimeric antibodies to explore the function of PD1 for experimental purposes. Antibodies such as anti-PD1 such as EH12.2H7 help in blocking PD1 interaction to study its role further.
Biological function summary

PD1 serves as an inhibitory receptor acting as a checkpoint in the immune system. It becomes part of an immune-suppressive complex when it binds with its ligands PD-L1 or PD-L2 which are expressed on various cell types including some tumor cells. This interaction suppresses the proliferation of T cells and cytokine production contributing to immune homeostasis. By controlling T cell activity PD1 limits autoimmunity but can also reduce the immune system's capability to attack cancer cells.

Pathways

PD1 functions in the immune checkpoint pathway a critical regulatory circuit in immune regulation. The engagement of PD1 with its ligands initiates a cascade that inhibits the function and proliferation of T cells through downstream SHP-2 phosphatase activity. This pathway frequently involves other regulatory proteins like CTLA-4 and is an important mechanism by which the body modulates immune responses. Related pathways often intersect with those involving T cell receptor signaling and contribute to the overall modulation of immune activity.

PD1 has a significant role in cancer and autoimmune disorders. PD1 expression can allow tumors to evade immune surveillance making PD1 a target for cancer therapies such as anti-PD1 antibodies which aim to block PD1 and restore T cell activity. The interaction of PD1 with cancer-related proteins like PD-L1 facilitates tumor immune evasion. In autoimmune disorders PD1’s regulation of immune balance can become dysregulated leading to persistent immune activation and tissue damage. Understanding PD1 and its interaction with proteins such as PD-L1 helps in developing therapeutic strategies for both cancer and autoimmune conditions.
style
left-column

Product protocols

style
left-column

Target data

Inhibitory receptor on antigen activated T-cells that plays a critical role in induction and maintenance of immune tolerance to self (PubMed : 21276005, PubMed : 31754127, PubMed : 32184441, PubMed : 37208329). Delivers inhibitory signals upon binding to ligands CD274/PDCD1L1 and CD273/PDCD1LG2 (PubMed : 21276005, PubMed : 26602187). Following T-cell receptor (TCR) engagement, PDCD1 associates with TCR-CD3 in the immunological synapse and directly inhibits T-cell activation (PubMed : 32184441). Suppresses T-cell activation through the recruitment of PTPN11/SHP-2 : following ligand-binding, PDCD1 is phosphorylated within the ITSM motif, leading to the recruitment of the protein tyrosine phosphatase PTPN11/SHP-2 that mediates dephosphorylation of key TCR proximal signaling molecules, such as ZAP70, PRKCQ/PKCtheta and CD247/CD3zeta (PubMed : 32184441).. The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival (PubMed : 28951311). The interaction with CD274/PDCD1L1 inhibits cytotoxic T lymphocytes (CTLs) effector function (PubMed : 28951311). The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (PubMed : 22658127, PubMed : 25034862, PubMed : 25399552).
See full target information PDCD1
style
left-column

Publications (10)

Recent publications for all applications. Explore the full list and refine your search

International journal of molecular sciences 26: PubMed40332328

2025

Comparison of the L3-23K and L5-Fiber Regions for Arming the Oncolytic Adenovirus Ad5-Delta-24-RGD with Reporter and Therapeutic Transgenes.

Applications

Unspecified application

Species

Unspecified reactive species

Aleksei A Stepanenko,Anastasiia O Sosnovtseva,Marat P Valikhov,Anastasiia A Vasiukova,Olga V Abramova,Anastasiia V Lipatova,Gaukhar M Yusubalieva,Vladimir P Chekhonin

Medicina (Kaunas, Lithuania) 61: PubMed40005306

2025

Lymphocyte Inhibition Mechanisms and Immune Checkpoints in COVID-19: Insights into Prognostic Markers and Disease Severity.

Applications

Unspecified application

Species

Unspecified reactive species

Martina Schniederova,Anna Bobcakova,Marian Grendar,Adam Markocsy,Andrej Ceres,Michal Cibulka,Dusan Dobrota,Milos Jesenak

Current oncology (Toronto, Ont.) 31:1701-1712 PubMed38668032

2024

Soluble Immune Checkpoint Molecules as Predictors of Efficacy in Immuno-Oncology Combination Therapy in Advanced Renal Cell Carcinoma.

Applications

Unspecified application

Species

Unspecified reactive species

Kosuke Ueda,Keiichiro Uemura,Naoki Ito,Yuya Sakai,Satoshi Ohnishi,Hiroki Suekane,Hirofumi Kurose,Tasuku Hiroshige,Katsuaki Chikui,Kiyoaki Nishihara,Makoto Nakiri,Shigetaka Suekane,Sachiko Ogasawara,Hirohisa Yano,Tsukasa Igawa

Cancers 15: PubMed37760608

2023

Association between Expression and Immune Dysregulation in Pancreatic Ductal Adenocarcinoma: Insights from Comprehensive Immune Profiling of Peripheral Blood Mononuclear Cells.

Applications

Unspecified application

Species

Unspecified reactive species

Arenida Bartkeviciene,Aldona Jasukaitiene,Inga Zievyte,Darius Stukas,Sandra Ivanauskiene,Daiva Urboniene,Toivo Maimets,Kristaps Jaudzems,Astra Vitkauskiene,Jason Matthews,Zilvinas Dambrauskas,Antanas Gulbinas

Cancer medicine 12:17648-17659 PubMed37501393

2023

Serum soluble immune checkpoint levels predict cervical lymph node metastasis of differentiated thyroid carcinoma patients.

Applications

Unspecified application

Species

Unspecified reactive species

Yi Shao,Xinru Gui,Yuxin Wang,Lei Sheng,Dong Sun,Qingdong Zeng,Huayang Wang

International journal of molecular sciences 24: PubMed37446260

2023

Tumor-TME Bipartite Landscape of PD-1/PD-L1 in Endometrial Cancers.

Applications

Unspecified application

Species

Unspecified reactive species

Raed Sulaiman,Pradip De,Jennifer C Aske,Xiaoqian Lin,Adam Dale,Nischal Koirala,Kris Gaster,Luis Rojas Espaillat,David Starks,Nandini Dey

Oncoimmunology 11:2096359 PubMed35813574

2022

PD-1 is expressed in cytotoxic granules of NK cells and rapidly mobilized to the cell membrane following recognition of tumor cells.

Applications

Unspecified application

Species

Unspecified reactive species

Cecilia Pesini,Sandra Hidalgo,Maykel A Arias,Llipsy Santiago,Carlota Calvo,Maitane Ocariz-Díez,Dolores Isla,Pilar M Lanuza,M José Agustín,Eva M Galvez,Ariel Ramírez-Labrada,Julián Pardo

International journal of molecular sciences 23: PubMed35806053

2022

Synthesis and Biological Evaluation of Small Molecules as Potential Anticancer Multitarget Agents.

Applications

Unspecified application

Species

Unspecified reactive species

Alberto Pla-López,Raquel Castillo,Rocío Cejudo-Marín,Olaya García-Pedrero,Mariam Bakir-Laso,Eva Falomir,Miguel Carda

Molecules (Basel, Switzerland) 27: PubMed35408446

2022

Novel 1,2,3-Triazole-Coumarin Hybrid Glycosides and Their Tetrazolyl Analogues: Design, Anticancer Evaluation and Molecular Docking Targeting EGFR, VEGFR-2 and CDK-2.

Applications

Unspecified application

Species

Unspecified reactive species

Wael A El-Sayed,Fahad M Alminderej,Marwa M Mounier,Eman S Nossier,Sayed M Saleh,Asmaa F Kassem

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 115:229-236 PubMed34910956

2021

Circulating level of sPD-1 and PD-1 genetic variants are associated with hepatitis B infection and related liver disease progression.

Applications

Unspecified application

Species

Unspecified reactive species

Pham Thi Minh Huyen,Dang Thi Ngoc Dung,Peter Johann Weiß,Phan Quoc Hoan,Dao Phuong Giang,Ngo Thi Uyen,Nguyen Van Tuan,Ngo Tat Trung,Thirumalaisamy P Velavan,Le Huu Song,Nghiem Xuan Hoan
View all publications
style
left-column
style
left-column
websiteProtocolBooklet
en
style
right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com